95035 20200904094319.0 doi 10.1093/jac/dkz346 sideral 115376 ART-2019-115376 eng Del Barrio-Tofiño, Ester Association between Pseudomonas aeruginosa O-antigen serotypes, resistance profiles and high-risk clones: results from a Spanish nationwide survey 2019 Access copy available to the general public Unrestricted Objectives: To evaluate the correlation of O-antigen serotypes with resistance profiles and high-risk clones in a Spanish nationwide survey. Methods: Up to 30 consecutive healthcare-associated Pseudomonas aeruginosa isolates were collected during October 2017 from each of 51 hospitals (covering all Spanish regions) with a total of 1445 isolates studied. MICs of 13 antipseudomonal agents and MDR/XDR profiles had been previously determined, as well as whole-genome sequences of 185 representative XDR isolates. O-antigen serotypes (O1–O16) were determined by agglutination using serotype-specific antisera (BioRad). The Pseudomonas aeruginosa serotyper (PAst) program was used for in silico serotyping. Results: The most frequent serotypes were O6 (17.8%), O1 (15.4%) and O11 (13.3%). In contrast, the most frequent serotype among XDR isolates (17.3%) was O4 (34.1%), distantly followed by O11 (15.9%). Within serotypes, XDR phenotypes were more frequent for O12 (60.0%) and O4 (57.3%). The most frequent clone among the XDR isolates was ST175 (40.9%), followed by CC235 (10.7%), ST308 (5.2%) and CC111 (3.6%). Up to 81.6%of XDR ST175 isolates typed O4, whereas 18.4% were non-typeable. O4 genotype was detected in all sequenced (n=55) ST175 isolates. On the other hand, CC235 and ST308 were associated with O11, whereas CC111 was linked to serotype O12. Conclusions: O4 serotype is linked to the MDR/XDR profile of widespread ST175 (typically only susceptible to colistin, amikacin and the novel combinations ceftolozane/tazobactam and ceftazidime/avibactam) and therefore, after local validation, its detection in the microbiology laboratory might be useful for guiding semi-empirical antipseudomonal therapies and infection control measures in Spanish hospitals. info:eu-repo/grantAgreement/ES/ISCIII/PI15-00088 info:eu-repo/grantAgreement/ES/ISCIII/PI18-00076 info:eu-repo/grantAgreement/ES/MINECO-FEDER/ISCIII-REIPI-RD16-0016 info:eu-repo/semantics/openAccess All rights reserved http://www.europeana.eu/rights/rr-f/ 5.439 2019 INFECTIOUS DISEASES 10 / 93 = 0.108 2019 Q1 T1 PHARMACOLOGY & PHARMACY 22 / 270 = 0.081 2019 Q1 T1 MICROBIOLOGY 24 / 134 = 0.179 2019 Q1 T1 2.23 2019 Infectious Diseases 2019 Q1 Pharmacology (medical) 2019 Q1 Pharmacology 2019 Q1 Microbiology (medical) 2019 Q1 info:eu-repo/semantics/article info:eu-repo/semantics/acceptedVersion Sánchez-Diener, Irina Zamorano, Laura Cortes-Lara, Sara López-Causapé, Carla Cabot, Gabriel Bou, Germán Martínez-Martínez, Luis Oliver, Antonio on behalf of the GEMARA-SEIMC/REIPI Pseudomonas study group (orcid)0000-0002-2519-701X Castillo-García, Francisco Javier Universidad de Zaragoza (orcid)0000-0002-9742-1463 Seral, Cristina Universidad de Zaragoza 1008 630 Universidad de Zaragoza Dpto. Microb.Med.Pr.,Sal.Públ. Área Microbiología 74, 11 (2019), 3217-3220 J. antimicrob. chemother. The Journal of antimicrobial chemotherapy 1460-2091 141090 http://zaguan.unizar.es/record/95035/files/texto_completo.pdf Postprint 50331 http://zaguan.unizar.es/record/95035/files/texto_completo.jpg?subformat=icon icon Postprint oai:zaguan.unizar.es:95035 articulos driver 2020-09-04-08:30:34 ARTICLE